SecurityGGP / GGP, Inc. (370023103)
IndustryReal Estate Investment Trusts
Institutional Owners18
Institutional Shares50,650,684 - 5.28%
Common Shares Outstanding958,391,980 shares (as of 2018-03-31)
Institutional Value$ 1,264,367,000 USD
Related GGP.PRA / General Growth Properties, Inc.
GGP / General Growth Properties, Inc.

Institutional Stock Ownership and Shareholders()

GGP, Inc. (NYSE:GGP) has 18 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 50,650,684 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, BlackRock Group LTD, BlackRock Investment Management, LLC, BlackRock Advisors LLC, BlackRock Japan Co. Ltd, Group One Trading, L.p., Group One Trading, L.p., Gulf International Bank (UK) Ltd, and Mizuho Asset Management Co.,Ltd..
GGP, Inc. (NYSE:GGP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 21,169,026 21,961,063 3.74 584,265 548,587 -6.11
2017-05-01 13F-HR Spot Trading L.L.C 10,501 0 -100.00 262 0
2018-05-15 13F-HR BARR E S & CO 34,225 25,225 -26.30 801 516 -35.58
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 905,400 320,600 -64.59 21,177 6,559 -69.03
2016-11-14 13F-HR MASON STREET ADVISORS, LLC 78,993 2,180
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,369,323 1,422,939 3.92 37,793 35,545 -5.95
2017-05-15 13F-HR R&F Capital Advisors LP 15,838 0 -100.00 396 0
2017-02-10 13F-HR BlackRock Fund Advisors 18,798,914 17,469,089 -7.07 518,850 436,378 -15.90
2018-07-20 13F-HR WHITTIER TRUST CO 0 78 0 2
2018-05-14 13F-HR SRS Capital Advisors, Inc. 523 10
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 121,800 302,100 148.03 2,849 6,181 116.95
2017-05-01 13F-HR Spot Trading L.L.C Put 40,000 0 -100.00 999 0
2017-01-13 13F-HR MetLife Securities, Inc 171 1,576 821.64 5 39 680.00
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 293,087 0 -100.00 7,321 0 -100.00
2017-01-27 13F-HR Forum Securities Ltd 2,741 3,141 14.59 76 78 2.63
2017-02-10 13F-HR BlackRock Japan Co. Ltd 812,692 862,061 6.07 22,430 21,534 -3.99
2018-05-11 13F-HR CIBC WORLD MARKETS CORP 126,277 81,880 -35.16 2,954 1,675 -43.30
2017-02-10 13F-HR BlackRock Group LTD 7,477,528 7,383,179 -1.26 206,380 184,432 -10.63
2017-02-10 13F-HR BlackRock Advisors LLC 577,863 926,423 60.32 15,949 23,142 45.10
2017-05-12 13F-HR/A DELTA LLOYD NV 512,783 0 -100.00 12,809 0 -100.00
2018-07-05 13F-HR Gulf International Bank (UK) Ltd 191,334 225,214 17.71 3,914 4,601 17.55
2018-05-11 13F-HR MUHLENKAMP & CO INC Put 47,500 0 -100.00 1,111 0 -100.00
2016-11-14 13F-HR Mizuho Asset Management Co.,Ltd. 164,200 4,532
2018-05-14 13F-HR EII CAPITAL MANAGEMENT, INC. 43,600 43,600 0.00 1,100 1,079 -1.91

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Merger Arbitrage Mondays - July 16, 2018

2018-07-16 seekingalpha
DOJ's challenge to AT&T and Time Warner’s merger could affect the bidding war between Disney and Comcast for Twenty-First Century Fox. (139-1)

This Is A Fat Pitch: Swing At It

2018-07-10 seekingalpha
We have written on the value of a creating a globally diverse REIT portfolio before. For those not wanting to go through the trouble, BPY shares accomplish some of that with a single purchase. It is rare to find a real estate company with a dividend yield over 6% with such a superb portfolio. The built in diversification of office, retail and opportunistic investments along with a global portfolio add to the appeal. (1-0)

Merger Arbitrage Mondays - July 9, 2018

2018-07-09 seekingalpha
Perry Ellis International (PERY) confirmed receipt of a non-binding, unsolicited proposal from privately-held Randa Accessories Leather Goods. (136-2)

A Primer On Brookfield Asset Management

2018-07-09 seekingalpha
Brookfield (BAM), an under-the-radar company, is one of the largest alternative asset managers in the world. (9-2)

Fantastic Yields And Where To Find Them

2018-07-07 seekingalpha
We have always held the view that a strong portfolio is a non-US centric, globally diversified portfolio. (1-0)

CUSIP: 370023103